MNK-6105
- Generic Name
- MNK-6105
Yaqrit Advances L-ornithine Phenylacetate to Phase 3 for Acute Hepatic Encephalopathy Treatment
• Yaqrit's subsidiary Amalive is preparing to launch Phase 3 trials in 2025 for L-ornithine phenylacetate (OPA), an ammonia scavenger acquired from Mallinckrodt Pharmaceuticals, targeting acute hepatic encephalopathy.
• The company plans parallel development of oral formulations for hepatic encephalopathy prevention and urea cycle disorders, building on previous clinical data showing faster ammonia reduction compared to standard care.
• With 200,000 annual US hospitalizations for acute hepatic encephalopathy and a 40-50% recurrence rate within one year, OPA addresses a significant unmet medical need in advanced liver disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath